


Product Details

Catalog No.	ATAD00005
INN (International Nonproprietary Name)	Daclizumab
Purity	>95%

SDS-PAGE image




Concentration	1mg/ml
Formulation	PBS buffer PH7.5
Source	CHO cells
Endotoxin level	Please contact with the lab for this information.
Note	For research use only .

Bioactivity

Description	<p>Humanized IgG1 Mab that binds to the human interleukin-2 receptor (anti-Tac or anti-CD25). Daclizumab is a composite of human (90%) and murine (10%) antibody sequences. The human sequences were derived from the constant domains of human IgG1 and the variable framework regions of the Eu myeloma antibody. The murine sequences were derived from the complementarity-determining regions of a murine anti-Tac antibody. On 22 April 2008, Roche Registration Limited chose to voluntarily withdraw the marketing authorization for their product Zenapax (daclizumab), as indicated for the prophylaxis of acute organ rejection in de novo allogeneic renal transplantation and used concomitantly with an immunosuppressive regimen like cyclosporine and corticosteroids in patients who are not highly immunized, for commercial reasons and confirmed that this decision was not related to any safety concerns associated with the use of</p>
-------------	---

Zenapax (daclizumab) 2. Regardless of the withdrawal of Zenapax, Biogen and Abbvie's Zinbryta (daclizumab), as indicated for the treatment of adult patients with relapsing forms of multiple sclerosis, was approved for use by the FDA in 2016.

Bioactivity



Alternative names	BIIB019, DAC HYP
Specificity target name; species	IL2RA[Homo sapiens]
Species	Humanized
Receptor identification	IgG1-kappa

Chemistry

MV	142612.1 Da
CAS	152923-56-3
Storage	<p>Use a manual defrost freezer and avoid repeated freeze-thaw cycles.</p> <p>Store at +4°C short term (1-2 weeks).</p> <p>Store at -20 °C 12 months.</p> <p>Store at -80°C long term.</p>